Gain Therapeutics Inc (GANX)
Healthcare
Biotechnology
1.70 $
-4.5%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Gain Therapeutics Inc (GANX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 97.6% of the shares are freely tradable; institutional investors hold 19.2%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
19.2%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
2.3%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
97.6%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
9.3%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
43Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Marshall Wace Asset Management Ltd | 4.15 | 1,769,788 | +6.5 | 03/31/2026 |
| Potomac Capital Management, Inc. | 2.36 | 1,008,600 | -0.1 | 03/31/2026 |
| JONES FINANCIAL COMPANIES LLLP | 1.48 | 631,615 | -10.1 | 03/31/2026 |
| Vanguard Group Inc | 1.34 | 569,901 | +6.7 | 12/31/2025 |
| CAMBRIDGE Invest RESEARCH ADVISORS, INC. | 1.33 | 568,645 | +0.0 | 03/31/2026 |
| Geode Capital Management, LLC | 1.05 | 447,342 | +12.4 | 03/31/2026 |
| Susquehanna International Group, LLP | 1.01 | 431,267 | -37.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 0.94 | 399,886 | +0.0 | 03/31/2026 |
| GSA Capital Partners LLP | 0.73 | 312,467 | +1,426.3 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Institutional Extnd Mkt Idx Tr | 1.01 | 432,457 | +8.1 | 04/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.